• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form S-3/A filed by VolitionRX Limited

    4/14/25 9:39:41 AM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $VNRX alert in real time by email
    S-3/A 1 vnrx_s3a.htm FORM S-3/A vnrx_s3a.htm

     As Filed with the Securities and Exchange Commission on April 11, 2025

     

    Registration No. 333-283088

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    Amendment No. 1

    to

    Form S-3

     

    REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

     

    VOLITIONRX LIMITED

    (Exact Name of Registrant as Specified in its Charter)

     

    Delaware

     

    91-1949078

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

     

    1489 West Warm Springs Road, Suite 110

    Henderson, Nevada 89014

    +1 (646) 650-1351

    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

     

    Agents and Corporations, Inc.

    1201 Orange Street, Suite 600

    Wilmington, Delaware 19801

    +1 (800) 759-2248

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

    Copies to:

     

    Marc G. Alcser, Esq.

    Stradling Yocca Carlson & Rauth LLP

    660 Newport Center Drive, Suite 1600

    Newport Beach, California 92660

    +1 (949) 725-4000

     

    Approximate date of commencement of proposed sale to the public: From time to time after the effective date of this registration statement.

     

    If the only securities being registered on this form are being offered pursuant to dividend or interest reinvestment plans, please check the following box. ☐

     

    If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box. ☒

     

    If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

     

    If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

     

    If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☐

     

    If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ☐

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b–2 of the Exchange Act.

     

    Large accelerated filer

    ☐

    Accelerated filer

    ☐

    Non-accelerated filer

    ☒

    Smaller reporting company

    ☒

     

     

    Emerging growth company

    ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

    The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.

     

     

     

     

    EXPLANATORY NOTE

     

    This Pre-Effective Amendment No. 1 (this “Pre-Effective Amendment”) is being filed to amend the Registration Statement on Form S-3 (File No. 333-283088) originally filed by the registrant on November 8, 2024 (the “Registration Statement”) solely for the purpose of (i) updating the Filing Fee Table to reflect the revised amount of remaining unsold securities to be included on the Registration Statement pursuant to Rule 415(a)(6) that were registered on a previously filed registration statement and the resulting fee offsets, and (ii) to file an updated consent of Sadler, Gibb and Associates, LLC, the registrant’s independent registered public accounting firm. Accordingly, this Pre-Effective Amendment consists only of the facing page, this Explanatory Note, the amended Exhibit Index, and the signature pages. The remainder of the Registration Statement remains unchanged.

     

     

    II-2

     

     

    Item 16. Exhibits

     

     

     

     

     

    Incorporated by Reference

     

    Exhibit

    Number

     

    Exhibit Description

     

    Form

     

    File No.

     

    Exhibit

     

    Filing

    Date

     

    Filed

    Herewith

     

     

     

     

     

     

     

     

     

     

     

     

     

    1.1*

     

    Form of Underwriting Agreement.

     

     

     

     

     

     

     

     

     

     

    3.1

     

    Second Amended and Restated Certificate of Incorporation, as amended and currently in effect.

     

    S-8

     

    333-280974

     

    4.2

     

    7/24/24

     

     

    3.2

     

    Amended and Restated Bylaws, as amended and currently in effect.

     

    10-Q

     

    001-36833

     

    3.2

     

    5/13/24

     

     

    4.1

     

    Specimen Common Stock Certificate.

     

    10-SB

     

    000-30402

     

    3(A)

     

    12/6/99

     

     

    4.2*

     

    Form of Common Stock Warrant Agreement and Warrant Certificate.

     

     

     

     

     

     

     

     

     

     

    4.3*

     

    Form of Unit Agreement.

     

     

     

     

     

     

     

     

     

     

    5.1**

     

    Opinion of Stradling Yocca Carlson & Rauth LLP.

     

     

     

     

     

     

     

     

     

     

    23.1

     

    Consent of Independent Registered Public Accounting Firm.

     

     

     

     

     

     

     

     

     

    X

    23.2**

     

    Consent of Stradling Yocca Carlson & Rauth LLP (included in Exhibit 5.1).

     

     

     

     

     

     

     

     

     

     

    24.1**

     

    Power of Attorney (included on the signature page to the initial filing of this registration statement).

     

     

     

     

     

     

     

     

     

     

    107

     

    Filing Fee Table.

     

     

     

     

     

     

     

     

     

    X

     

    *

    To be filed by amendment or as an exhibit to a report pursuant to Section 13(a) or 15(d) of the Exchange Act and incorporated herein by reference, if applicable.

     

     

    **

    Previously Filed.

     

     

    II-3

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this Amendment No. 1 to registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Dubai, United Arab Emirates, on April 11, 2025.

     

     

    VOLITIONRX LIMITED

     

     

     

    By:

    /s/ Cameron Reynolds

     

     

    Cameron Reynolds

     

     

    President and Chief Executive Officer

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Amendment No. 1 to registration statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature

     

    Title

     

    Date

     

     

     

     

     

    /s/ Cameron Reynolds

     

    President, Chief Executive Officer and Director

     

    April 11, 2025

    Cameron Reynolds

     

    (Principal Executive Officer)

     

     

     

     

     

     

     

    /s/ Terig Hughes

     

    Chief Financial Officer and Treasurer

     

    April 11, 2025

    Terig Hughes

     

    (Principal Financial and Accounting Officer)

     

     

     

     

     

     

     

    /s/ Rodney Gerard Rootsaert

     

    Secretary

     

    April 11, 2025

    Rodney Gerard Rootsaert

     

     

     

     

     

     

     

     

    *

     

    Director

     

    April 11, 2025

    Guy Innes

     

     

     

     

     

     

     

     

     

    *

     

    Director

     

    April 11, 2025

    Dr. Alan Colman

     

     

     

     

     

     

     

     

     

    *

     

    Director

     

    April 11, 2025

    Dr. Phillip Barnes

     

     

     

     

     

     

     

     

     

    *

     

    Director

     

    April 11, 2025

    Kim Nguyen

     

     

     

     

     

     

     

     

     

    *

     

    Director

     

    April 11, 2025

    Mickie Henshall

     

     

     

     

     

     

     

     

     

    *

     

    Director

     

    April 11, 2025

    Dr. Ethel Rubin

     

     

     

     

     

     

     

     

     

    *

     

    Director

     

    April 11, 2025

    Timothy Still

     

     

     

     

     

     

     

     

     

    * By:  /s/ Cameron Reynolds

     

    Attorney-in-fact

     

    April 11, 2025

    Cameron Reynolds

     

     

     

     

     

     

    II-4

     

    Get the next $VNRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VNRX

    DatePrice TargetRatingAnalyst
    4/8/2025$2.50Buy
    H.C. Wainwright
    2/1/2023Buy → Hold
    The Benchmark Company
    2/17/2022$8.00 → $7.00Overweight
    Cantor Fitzgerald
    11/16/2021$10.00 → $9.00Buy
    Aegis Capital
    More analyst ratings

    $VNRX
    SEC Filings

    View All

    VolitionRX Limited filed SEC Form 8-K: Leadership Update

    8-K - VOLITIONRX LTD (0000093314) (Filer)

    12/11/25 5:00:30 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 10-Q filed by VolitionRX Limited

    10-Q - VOLITIONRX LTD (0000093314) (Filer)

    11/13/25 4:18:25 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    VolitionRX Limited filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - VOLITIONRX LTD (0000093314) (Filer)

    11/13/25 4:12:56 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $VNRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Reynolds Cameron John bought $7,000 worth of shares (20,000 units at $0.35), increasing direct ownership by 0.79% to 2,554,847 units (SEC Form 4)

    4 - VOLITIONRX LTD (0000093314) (Issuer)

    11/17/25 1:12:19 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Chief Medical Officer Retter Andrew covered exercise/tax liability with 4,588 shares, decreasing direct ownership by 3% to 146,568 units (SEC Form 4)

    4 - VOLITIONRX LTD (0000093314) (Issuer)

    11/4/25 4:01:54 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    GC - Volition Diagnostics Plummer Nicholas covered exercise/tax liability with 5,647 shares, decreasing direct ownership by 3% to 194,084 units (SEC Form 4)

    4 - VOLITIONRX LTD (0000093314) (Issuer)

    11/4/25 4:01:42 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $VNRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Reynolds Cameron John bought $7,000 worth of shares (20,000 units at $0.35), increasing direct ownership by 0.79% to 2,554,847 units (SEC Form 4)

    4 - VOLITIONRX LTD (0000093314) (Issuer)

    11/17/25 1:12:19 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    President and CEO Reynolds Cameron John bought $56,100 worth of shares (110,000 units at $0.51), increasing direct ownership by 5% to 2,534,847 units (SEC Form 4)

    4 - VOLITIONRX LTD (0000093314) (Issuer)

    10/15/25 4:05:45 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Director Innes Guy Archibald bought $49,038 worth of shares (96,153 units at $0.51), increasing direct ownership by 10% to 1,062,967 units (SEC Form 4)

    4 - VOLITIONRX LTD (0000093314) (Issuer)

    10/15/25 4:05:33 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $VNRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on VolitionRx with a new price target

    H.C. Wainwright initiated coverage of VolitionRx with a rating of Buy and set a new price target of $2.50

    4/8/25 8:02:28 AM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    VolitionRx downgraded by The Benchmark Company

    The Benchmark Company downgraded VolitionRx from Buy to Hold

    2/1/23 7:40:33 AM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Cantor Fitzgerald resumed coverage on VolitionRx with a new price target

    Cantor Fitzgerald resumed coverage of VolitionRx with a rating of Overweight and set a new price target of $7.00 from $8.00 previously

    2/17/22 9:10:02 AM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $VNRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Volition Solves Liquid Biopsy's "Needle in a Haystack" Problem; Achieves 180-fold (18,000%) Enrichment

    HENDERSON, Nev., Dec. 11, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, announces preprint availability of a new manuscript entitled "Direct analysis of transcription factor protected cfDNA in plasma by ChIP-seq: Measurement of altered CTCF binding in cancer is a novel biomarker for liquid biopsy". This paper showcases both a new method, Capture-Seq™, and new biomarkers for the detection of cancer, holding the promise of accurate, low-cost tests for a wide range of cancers.   Physical enrichment of ultrashort DNA fragments bound to a transcription factor is a key breakthrough allowing for the quantification

    12/11/25 9:00:00 AM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Volition Announces Two Abstracts were Presented at the North America Conference on Lung Cancer

    HENDERSON, Nev.,, December 8, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, announces the presentation of two abstracts at the North America Conference on Lung Cancer (NACLC) in Chicago recently. The posters highlighted the use of its Nu.Q® Cancer assays in the management of lung cancer patients. Prognostic Value of Circulating H3K27Me3-Nucleosomes in Newly Diagnosed Lung Cancer Patients Professor Lea Payen, Professor in Toxicology and Biochemistry, Claude Bernard University of Lyon and Hospices Civils de Lyon, France, said: "This large-scale study demonstrates that Nu.Q®-H3K27Me3 levels increase with cancer disease stages and import

    12/8/25 9:00:00 AM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    VolitionRx Limited Announces Inclusion of its Nu.Q® NETs Assay as Innovative Biomarker in France's Real-World Evaluation of Early Detection of Sepsis

    HENDERSON, Nev., Dec. 4, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, today announces the inclusion of its Nu.Q® NETs H3.1 assay in "DETECSEPS", a real-world evaluation of early detection of sepsis. DETECSEPS Consortium was awarded winner of the "Challenge Prevention" call for proposals launched by the French Health Innovation Agency and operated by the Banque Publique d'Investissement, as part of the France 2030 plan, during the official ceremony held yesterday,  December 3, in Paris, France.  This consortium will be financed with approximately €6.3 million (~$7.3 million) by the French government and is a key national strategic axi

    12/4/25 9:00:00 AM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $VNRX
    Leadership Updates

    Live Leadership Updates

    View All

    Volition Issues Business Review 2024

    HENDERSON, Nev., Jan. 8, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, has issued a Business Review of 2024, outlining its key highlights from the past year. Volition's major achievements in 2024 include: Expanded access to the Nu.Q® Vet Cancer Test – now available for purchase in 20 countries worldwide.Sold over 110,000 Nu.Q® Vet Cancer Tests in the first three quarters 2024.Hosted Satellite Symposium at European Society of Intensive Care Medicine 2024 showcasing Nu.Q® NETs clinical utility in over 3,000 intensive care sepsis patients.Continued to strengthen our strategic patent portfolio.Made significant progress a

    1/8/25 8:30:00 AM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Volition Appoints Timothy I. Still as Chairman

    HENDERSON, Nev., Nov. 6, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, has appointed Timothy Still as Chairman of its board of directors, effective November 06, 2024. Mr. Still is currently Chairman and CEO of TSTILL Enterprises LLC, and an Operating Partner with REVIVAL Healthcare. An accomplished executive with a career spanning over 35 years in medical diagnostics, devices and digital health, his background includes extensive experience in designing and implementing highly focused commercial and business development

    11/6/24 4:10:00 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Volition Appoints Dr. Ethel Rubin as an Independent Director

    HENDERSON, Nev., Sept. 30, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, has appointed Dr. Ethel Rubin to its board of directors, as an independent director, effective September 30, 2024. Dr. Rubin has also been appointed as a member of the Audit Committee and the Compensation Committee. Dr. Rubin has over 20 years' experience within the life sciences sector, leading healthcare innovation and commercialization strategies for a wide range of organizations – from early-stage operations to large global corporate businesses

    9/30/24 4:10:00 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $VNRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    $VNRX
    Financials

    Live finance-specific insights

    View All

    SEC Form SC 13G filed by VolitionRX Limited

    SC 13G - VOLITIONRX LTD (0000093314) (Subject)

    11/14/24 4:05:14 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G filed by VolitionRX Limited

    SC 13G - VOLITIONRX LTD (0000093314) (Subject)

    11/14/24 3:40:04 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G/A filed by VolitionRX Limited (Amendment)

    SC 13G/A - VOLITIONRX LTD (0000093314) (Subject)

    2/14/24 4:05:45 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    VolitionRx Limited Schedules Third Quarter 2025 Earnings Conference Call and Business Update

    Conference call to take place on Friday, November 14 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev., Nov. 10, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition") today announces that it will host a conference call on Friday, November 14 at 8.30 a.m. U.S. Eastern Time to discuss its financial and operating results for the third quarter of 2025 and to provide a business update. Details of this event can be found below. Event:   VolitionRx Limited Third Quarter 2025 Earnings and Business Update Conference Call Date:     Friday, November 14, 2025Time:    8:30 a.m. U.S. Eastern Time/2.30 p.m. Central European Time U.S. & Canada Dial-in: 1-877-407-9716 (toll free)U.K. Dial-in: 0 800

    11/10/25 8:45:00 AM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    VolitionRx Limited Schedules Second Quarter 2025 Earnings Conference Call and Business Update

    Conference call to take place on Friday, August 15 at 8:30 a.m. U.S Eastern Time HENDERSON, Nev., Aug. 8, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition") today announces that it will host a conference call on Friday, August 15 at 8.30 a.m. U.S. Eastern Time to discuss its financial and operating results for the second quarter of 2025 and to provide a business update. Details of this event can be found below. Event:   VolitionRx Limited Second Quarter 2025 Earnings and Business Update Conference Call Date:     Friday, August 15, 2025Time:    8:30 a.m. U.S. Eastern Time/2.30 p.m. Central European Time U.S. & Canada Dial-in: 1-877-407-9716 (toll free)U.K. Dial-in: 0 800 756 34

    8/8/25 8:30:00 AM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    VolitionRx Limited Announces First Quarter 2025 Financial Results and Business Update

    Conference call to discuss financial and operational results scheduled for Friday, May 16 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev., May 15, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, today announces financial results and a business update for the first quarter ended March 31, 2025.  Volition management will host a conference call tomorrow, May 16 at 8:30 a.m. U.S. Eastern Time to discuss these results. Conference call details can be found below. Cameron Reynolds, President and Group Chief Executive Officer, said: "2025 is a pivotal year for Volition as we focus on commercializing our ground breaking Nu.Q® platform in the hum

    5/15/25 5:37:00 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care